

PATTERN OF ANTIBIOTIC SUSCEPTIBILITY OF URINARY TRACT PATHOGENS AGAINST COMMONLY USED ANTIBIOTICS IN PATIENTS OF A TERTIARY CARE HOSPITAL OF DISTRICT SWAT

Sapna Anwar¹, Jasra Bibi², Farhat Ayub³, Hayat Ullah⁴, Salim Ullah⁵, Muhammad Arif Khan⁶, Inam Ullah^{*7}

^{1,2,3,4,5}Department of Microbiology, Government degree college Madyan Swat

⁶Department of Medical Lab Technology, University of Haripur

^{*7}Lecturer, Department of Microbiology, Government degree college Madyan Swat

^{*7}Inammicro@gmail.com

DOI: <https://doi.org/10.5281/zenodo.14898228>

Keywords

S. aureus, *E. coli*, *E. faecalis*, *P. aeruginosa*, , Disease; Urinary System

Article History

Received on 11 January 2025

Accepted on 11 February 2025

Published on 20 February 2025

Copyright @Author

Corresponding Author: *

Abstract

Background: Urinary tract infection is a widespread health condition and most commonly caused by bacteria. It is estimated that annually about 150 million cases of UTIs occur worldwide which is one of the key public health complications.

Objective: To determine the pattern of antibiotic susceptibility of urinary tract pathogens against commonly used antibiotics in patients of a tertiary care hospital of district Swat

Methodology: The current cross-sectional research was conducted at the Department of Microbiology, Government Degree College Madyan Swat and the Saidu Group of Teaching Hospital Swat. The study duration was six months from January 2024 to June 2024. A total of 100 patients were included in our study. 100 mid-stream urine samples were collected from both males and females with a urinary tract infection by using sterile urine containers. Further laboratory procedures were performed in the Department of Microbiology, Government Degree College Madyan Swat. Culturing was done for all the samples by using CLED media. The isolates were identified by using gram staining and conventional biochemical testing. Kirby-Bauer Antibiotic Susceptibility testing was done for all the isolates. Data were entered and analyzed in IBM SPSS-24.

Results: In the current study Gram-negative bacteria that was most frequently identified in UTIs was *E. coli*, while gram-positive bacteria that was frequently identified was *S. aureus* in suspected patients in Swat. The highest risk age groups for UTI were 16-30 years and 46-60 years. Among genders, females were more affected compared to males. Imipenem was the highly responsive drug for gram-negative and the highly responsive drug for gram-positive was Nitrofurantoin.

Conclusion: This study concludes that *E. coli* was the primary cause of UTI. The results of the antibiotic sensitivity test showed that the majority of the isolated bacteria in this investigation are resistant to routinely used antibiotics. Culture and sensitivity should be done before prescription of antibiotics.

INTRODUCTION

The urinary tract consist of organs like kidneys, ureters, bladder, and urethra, that are responsible for gathering, storing, and releasing urine from the body (1). Cystitis refers to an infection of the bladder while urethritis refers to an infection of the urethra. Pyelonephritis is an infection of the kidneys caused by bacteria that can travel through the ureters (2). Particularly in females with shorter and wider urethras, bacteria travel retrogradely from the fecal flora to the urinary system (3). Urinary tract infections are most commonly caused by bacteria. Bacteria from the gastrointestinal system that have colonized the pre-urethral region are the cause of UTIs. Gram-negative bacteria are typically found in recurrent infections, particularly when they are linked to nosocomial catheter-associated infections, stones, obstruction, and urologic manipulation. These species include *Pseudomonas*, *Escherichia coli*, *Proteus*, *Klebsiella*, *Enterobacter*, and *Serratia* (4-6). *Enterococcus faecalis*, *Staphylococcus aureus*, and *Staphylococcus epidermis* are other bacterial pathogens that are commonly isolated (7). The primary cause of urinary tract infections (UTIs) is *Escherichia coli* (8).

Urinary tract infection is a widespread health condition, produced by a varied group of bacteria and impacting human population (9). The risk of UTIs is higher in women, because it is known that asymptomatic bacteriuria is common during pregnancy (10). Due to its physical proximity to the vagina, the female urethra is susceptible to harm during sexual activity, and the moisture-rich environment of the perineum renders females more likely to become contaminated in their bladders (11). Prostatic hypertrophy nearly invariably complicates UTIs in older men, while postmenopausal women may have an elevated post-void residual volume (12). UTIs acquired in the community account for 80-85% of cases, *Escherichia coli* is the primary cause of UTIs, with *Staphylococcus saprophyticus* accounting for approximately 5-10% of cases. It is estimated that annually about 150 million cases of UTIs occur worldwide which is one of the key public health complications. More than 60% of women are affected by UTI at least one time in their life. (13, 14). In teenage girls and sexually active females, the rate of UTI is 10.57% higher than in men and the

most communal contributing organism is *Escherichia coli* (15).

In recent times due to misuse of antibiotics bacteria have evolved resistance to antibiotics in medical procedures (16). Uropathogens have developed antibiotic resistance and it is an increasingly common issue globally because of the widespread and excessive use of antibiotics, prior to urine culture, and the sensitivity of bacteria to antibiotics (17-21). In case of complications or if treatment does not work properly, culture of urine may be useful. In our setting, no such study has been carried out. This study was therefore carried out to determine the pattern of antibiotic susceptibility of urinary tract pathogens against commonly used antibiotics in patients of a tertiary care hospital of district Swat.

Materials and methods

The current cross-sectional research was conducted at the Department of Microbiology, Government Degree College Madyan Swat and the Saidu Group of Teaching Hospital Swat. The study duration was six months from January 2024 to June 2024. A total of 100 patients were included in our study. The criteria for inclusion were both males and females of all ages who who had urinary tract infection signs and symptoms and were referred by a physician whereas the exclusion criteria were those patients who were using antibiotics, patients who declined to take part in the study, and patients with recognized structural anomalies of the urogenital tract (based on history and medical records). 100 mid-stream urine samples were collected from both males and females with a urinary tract infection by using sterile urine containers. Further laboratory procedures were performed in the Department of Microbiology, Government Degree College Madyan Swat. Culturing was done for all the samples by using CLED media. The isolates were identified by using gram staining and conventional biochemical testing. Kirby-Bauer Antibiotic Susceptibility testing was done for all the isolates. The antibiotics that were used included Cefotaxime, Ciprofloxacin (5ug), Gentamicin (10ug), Amikacin (30ug), Meropenem (10ug), Penicillin (10ug), Chloramphenicol (30ug), Imipenem

(10ug), Fosfomycin (200ug), Clindamycin (2ug), Tazobactam (10ug), Nitrofurantoin (300ug), (30ug), Vancomycin Teicoplanin (30ug), Linezolid (30ug), Fosfomycin (200ug), Celestine (10ug), Tazobactam (10ug), and, Doxycycline (30ug). Data were entered and analyzed in IBM SPSS-24.

Results

In the present study, we collected 100 urine samples from UTI-suspected patients. From these samples different bacterial species were isolated, which included *Pseudomonas aeruginosa* 5 (5%), *E. coli* 63 (63.0%), *S. aureus* 12 (12.0%), *Enterobacter* species 12 (12.0%), and *E. fecalis* 8 (8.0%) (Figure 1). Among 100 participants 38 (38.0%) were male and 62 (62.0%) were females. *E. coli* was found in the 20 (31.74%) males and 43 (68.25%) females' urine samples, and *S. aureus* was present in 5 (41.66%) males and 7 (58.33%) in females, Similarly *Enterobacter* species, *Pseudomonas aeruginosa* and *Enterococcus fecalis* were found in 7 (58.33%), 5 (100%), 1 (12.5%) males, 5 (41.66%), 0 (0.0%) and 7 (87.5%) females respectively (Figure 2).

Most of the UTIs were found in the age interval 16-30 (29.0%) and 46-60 (29.0%) years. *E. coli* was isolated in 11 (17.64%) patients of age interval 1-15 years, 18 (28.57%) in 16-30 years, 3 (4.76%) in 31-45 years, 20 (31.74%) in 46-60 years, 7 (11.11%) in 61-75 years and 4 (6.34%) were found in age interval 76-90. Similarly *S. aureus* was found in 4 (33.3%) of age interval 1-15 year, 3 (25%) in 16-30 years, 0 (0.0%) in 31-45 years, 4 (33.3%) in 46-60 years, 1 (8.33%) in 61-75 years and no *S. aureus* was found in the age 76-90 years, whereas in *Enterobacter* species, *P. aeruginosa* and *E. fecalis* 2 (16.6%), 0 (0.0%), 0 (0.0%) of age interval 1-15 years, 3 (25.0%), 1 (20.0%), 4 (50.0%) in 16-30 years, 3 (25.0%), 0 (0.0%), 1 (12.5%) in age 31-45 years, 2 (16.6%), 2 (40.0%), 1 (12.5%) in 46-60 years, 1 (0.83%), 2 (40.0%), 2 (25.0%) in 61-75 years and 1 (8.33%), 0 (0.0%) and 0 (0.0%) were found in the age interval 76-90 years respectively as shown in figure 3.

S. aureus was sensitive to Doxycycline in 66.6% of cases and resistant in 33.3% of cases. 41.66% of cases were sensitive, 50.0% intermediate and 8.33% were resistant to Fucidic acid. Similarly, *S. aureus* was sensitive to Rifampicin in 83.33% of cases and resistant in 16.66% of cases. In the case of Penicillin,

G. S. aureus was not sensitive, 66.66% showed an intermediate response and 33.33% of cases were resistant. *S. aureus* was not sensitive to Teicoplanin whereas, in 41.66%, it showed intermediate response and resistance in 58.33% cases. In the case of Chloramphenicol *S. aureus* was sensitive in 83.3% of cases and intermediate in 16.66% of cases. In Nitrofurantoin *S. aureus* was sensitive in 83.33% of cases, in 8.33% of cases intermediate, and in 8.33% of cases resistant. In the case of Vancomycin, it was sensitive to 66.66% of cases and resistant to 33.33% of cases, whereas it was sensitive to 91.66% of cases and resistant to 8.33% cases to Erythromycin. 41.66% of cases were sensitive, 8.33% of intermediate and 50% cases were resistant to Fosfomycin. *S. aureus* was sensitive to 66.66% of cases and resistant to Ciprofloxacin in 33.33% of cases.

E. fecalis was sensitive to Doxycycline in 100.0% of cases and resistant in 0.0% of cases. 25% of cases were sensitive and 75% were resistant to Fucidic acid. Similarly, *E. fecalis* was sensitive to Rifampicin in 25% of cases, intermediate in 25%, and resistant in 50.0% of cases. In the case of Penicillin *G. E. fecalis* was sensitive 100.0%. *E. fecalis* was sensitive to Teicoplanin in 100.0% of cases. In the case of Chloramphenicol, *E. fecalis* was sensitive in 33.5% of cases and resistant in 62.5% of cases. In Nitrofurantoin *E. fecalis* was sensitive in 100.0% of cases. In the case of Vancomycin, it was resistant to 100.0% of the cases, whereas it was not sensitive in any case, 25.0% were intermediate and resistant to 75.0% cases in the case of Erythromycin. No case was seen as sensitive, 12.5% intermediate, and 87.5% cases were resistant to Fosfomycin. *S. aureus* was sensitive in 12.5% of cases and resistant to Ciprofloxacin in 87.5% of cases.

E. coli was sensitive to Cefotaxime in 19.04% of cases, intermediate in 7.9%, and resistant in 73.0% of cases. 76.1% of cases were sensitive, 11.11% intermediate and 12.6% were resistant to Tazobactam. Similarly, *E. coli* was sensitive to Ceftazidime in 19.0% cases and resistant in 80.9% of cases. In the case of Gentamycin, *E. coli* was sensitive in 33.33% and resistant in 66.66% of cases. *E. coli* was sensitive in 80.9% of cases to Sulbactam whereas in 12.6% it showed intermediate response and resistance in 6.3% cases. In the case of

Polymyxin B, *E. coli* was sensitive in 34.9% of cases, intermediate in 49.2% of cases, and 14.28% of cases were resistant. In Imipenem *E. coli* was sensitive in 85.7% cases, 7.9% cases intermediate, and 6.3% cases were resistant. In the case of Nitrofurantoin it was sensitive to 82.5% of cases, 12.6% of cases were intermediate, and 7.76% cases were resistant, whereas it was sensitive to 23.8% cases, intermediate to 12.6% and resistant to 63.4% cases in the case of Ciprofloxacin. 76.1% cases were sensitive, 11.11% intermediate and 12.69% cases were resistant to Amikacin. *E. coli* was sensitive in 47.6% of cases, intermediate in 22.22%, and resistant in 30.15% of cases to Colastine Sulphate. Enterobacter species were sensitive to Cefotaxime in 25% of cases and resistant in 75.0% of cases. 91.6% of cases were sensitive and 8.3% of cases were intermediate to Tazobactam. Similarly, Enterobacter species were sensitive to Ceftazidime in 50.0% of cases and resistant in 50.0% of cases. In the case of Gentamycin Enterobacter species were sensitive in 58.33% and resistant in 41.66% of cases. Enterobacter species were sensitive in 91.66% of cases to Sulbactam whereas in 8.33% it showed an intermediate response. In the case of Polymyxin Enterobacter species were sensitive in 75% of cases, intermediate in 8.33% of cases, and 16.66% of cases were resistant. In the case of Imipenem Enterobacter species were sensitive in 100.0% of cases. In the case of Nitrofurantoin, it was sensitive to 91.66% of cases and intermediate to 8.33% of cases, whereas it was

sensitive to 33.33% of cases and resistant to 66.66% of cases in the case of Ciprofloxacin. 100.0% of cases were sensitive to Amikacin. Enterobacter species were sensitive in 66.66 % of cases, intermediate in 8.33%, and resistant in 25.0% of cases to Colastine Sulphate.

Pseudomonas aeruginosa was sensitive to Cefotaxime in 20% of cases and resistant in 80.0% of cases. 80.0% of cases were sensitive and 20.0% of cases were resistant to Tazobactam. Similarly, *Pseudomonas aeruginosa* was resistant in 100.0% of cases to Ceftazidime. In the case of Gentamycin, *Pseudomonas aeruginosa* was sensitive in 60.0% and resistant in 40.0% of cases. *Pseudomonas aeruginosa* was sensitive in 60.0% of cases to Sulbactam whereas in 20.0% it showed an intermediate response and 20.0% showed a resistant response. In the case of Polymyxin B *Pseudomonas aeruginosa* was sensitive in 80% of cases, intermediate in 20.0% of cases, and 0.0% cases were resistant. In the case of Imipenem, *Pseudomonas aeruginosa* was sensitive in 80.0% of cases and 20.0% showed a resistant response. In the case of Nitrofurantoin, it was sensitive to 60.0% of cases and intermediate to 40.0% of cases, whereas it was sensitive to 60.0% of cases and resistant to 40.0% of cases in the case of Ciprofloxacin. 40.0% of cases were sensitive and 60.0% were resistant to Amikacin. *Pseudomonas aeruginosa* was sensitive in 40.0 % cases and resistant in 60.0% cases to Colastine Sulphate. (Table 1 and 2)




Figure 1: distribution of bacteria isolated from patients with UTI




Figure 2: Distribution of bacteria isolated from patients with UTI W.R.T to gender




Figure 3: Distribution of bacteria isolated from patients with UTI W.R.T to age

Table 1: Antibiotic susceptibility pattern of Gram Positive Bacteria in urine samples

Antibiotics	S. aureus			E. fecalis		
	S	I	R	S	I	R
Doxycycline	8	0	4	8	0	0
Fucidic Acid	5	6	2	2	0	6
Rifampicin	10	0	2	2	2	4
Penicillin G	0	8	4	8	0	0
Teicoplanin	0	5	7	8	0	0
Chloramphenicol	10	2	0	3	0	5
Nitrofurantoin	10	1	1	8	0	0
Vancomycin	8	0	4	0	0	8
Erythromycin	11	0	1	0	2	6
Fosfomycin	5	1	6	0	1	7
Ciprofloxacin	4	3	4	1	4	4

Table 2: Antibiotic susceptibility pattern of Gram Negative Bacteria in urine samples

Antibiotics	E. coli			Enterobacter species			P. aeruginosa		
	S	I	R	S	I	R	S	I	R
Cefotaxime	12	5	46	3	0	9	1	0	4
Tazobactam	48	7	8	11	1	0	4	0	1
Ceftazidime	12	0	51	6	0	6	0	0	5
Gentamycin	21	0	42	7	0	5	3	0	2
Sulbactam	51	8	4	11	1	0	3	1	1
Polymyxin B	22	31	9	9	1	2	4	1	0
Imipenem	54	5	4	12	0	0	4	0	1

Nitrofurantoin	52	8	3	11	1	0	3	2	0
Ciprofloxacin	15	8	40	4	0	8	3	0	2
Amikacin	48	7	8	12	0	0	2	0	3
Colastine Sulphate	30	14	19	8	1	3	2	0	3

Discussion

This research was conducted in order to find the causative pathogens of infection of the urinary tract in local people of Swat. Considering the pattern of antibiotic sensitivity against them. The urine samples were taken from both male and female patients. Males were 44 years old on average, while females were 35 years old. In the current study the frequency of UTI was greater in females (62%) compared to males (38%). This research is in accordance with the findings of the previous study (22). The increased frequency of UTI in women is in accordance with the previous study who reported more UTI cases as compared to male (23). Whereas in Hazara division it is more frequent in male may be due to their environmental conditions or male dominance (23). Five different types of pathogens were isolated including, *S. aureus*, *E. coli*, *P.aeruginosa*, *Enterobacter* species and *E.fecalis*.

The most prevalent urinary tract bacterium was *E. coli*, identified in 63.0% cases. *E. coli* was shown to be the most frequent bacteria in both the 2010 and 2013 studies carried out at the Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi, and the Mayo Hospital, Lahore. These studies accounted for 63% and 80% of all the culture-positive strains (24, 25). A comparable work carried out in Peshawar (KP) has reported comparable findings that indicate *E. coli* (77%) as the main uropathogens (26).

However, in two related investigations conducted in Canada and Ethiopia recently, the prevalence of *E. coli* as the causative agent of UTIs was shown to be 80–90% (27, 28). Conversely to this research, one research from Aurangabad showed *Klebsiella* as the most common isolate followed by *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa* (1). This difference could be due to environmental factors, socioeconomic status and host immunity and *Klebsiella* might be prevalent in these areas. In this research, 85% isolates of *E. coli* were Imipenem sensitive, the outcome being in line

with a comparable study done at AFIP two years prior and the study carried out in Peshawar (25, 26). These findings coincide with previous research conducted in India, which found that 96% of *E. Coli* isolates were imipenem-susceptible (29). Ciprofloxacin sensitivity of *E. coli* was 23.80% similar to research carried out in other Indian and Pakistani cities (25,26,29). But a study conducted in London shown that 94% of the *E. coli* strains were susceptible to ciprofloxacin, indicating a significant difference in the condition (30). These different outcomes obviously indicate the unnecessary ciprofloxacin utilization has resulted in declining sensitivity to these essential. The sensitivity of *E. coli* to Nitrofurantoin in this investigation was observed in 82.53%, but in a study conducted in London, it reached 94% (30). Nitrofurantoin sensitivity was seen in every isolate of enterococcus that we had. The profile of antibacterial sensitivity of *P.aeruginosa* showed that a high number of isolates were susceptible to Nitrofurantoin, Tazobactam, and Imipenem. Whereas in this study *P.aeruginosa* was resistant to Ceftazidime. These results of our study in this case are Varying from a previous study conducted at the AFIP laboratory (2010), where 86% of the strains showed susceptibility to Ceftazidime, Imipenem and Antipseudomonal penicillin's (76%) (25). The resistance of Ceftazidime could be due to its misuse which would have made *p. aeruginosa* more resistant. According to our research, which is similar with other local investigations, Enterobacteriaceae, including *E. coli* have higher antimicrobial sensitivity to Imipenem (26). *S. aureus* with a prevalence rate of 12.0 percent was shown to be the second most prevalent pathogen associated with UTIs.

This finding confirms the outcomes of Akerele et al (31). The research of Okonko et al (32) in Nigeria, Ibadan, and Manikandan et al (33) in India, who described the organism as the second most prevalent pathogen in UTIs, were also published, along with a 35.6% recovery rate for *S. aureus* in

Benin-city, Nigeria. These latest results thus validate *S. aureus* as a significant etiologic agent in UTIs. *S. aureus* susceptibility test results in the research demonstrated resistance 100% to penicillin and Teicoplanin, 41.6% to Fucidic acid and Fosfomycin. But *S. aureus* was sensitive to 83.3% chloramphenicol, Rifampicin and vancomycin, 66.6% to doxycycline, clindamycin and ciprofloxacin. As a result, it can be concluded that every *S. aureus* isolate linked to this UTI was Methicillin-resistant *S. aureus* (MRSA) and that their level of resistance to widely used medications was extremely high. This

finding has been extensively reported in the majority of MRSA infections (34, 35).

Conclusion

This study concludes that *E. coli* was the primary cause of UTI. The results of the antibiotic sensitivity test showed that the majority of the isolated bacteria in this investigation are resistant to routinely used antibiotics. Culture and sensitivity should be done before prescription of antibiotics. Antibiotic assay results may influence the physician's recommendation of antibiotics.

REFERENCES

- Otaejwo FD. Urinary tract infection among symptomatic outpatients visiting a tertiary hospital based in midwestern Nigeria. *Glob J Health Sci* [Internet]. 2013 Jan 13 [cited 2018 Jan 12];5(2):187-99.
- O.A A, H.E I, E.C A, E.G E, S.O O, E.O Amlscn U, et al. Incidence of Urinary Tract Infection among Pregnant Women Attending Antenatal Clinic at Federal Medical Centre, Bida, Niger-State, North Central Nigeria. *Am J Infect Dis Microbiol* [Internet]. 2014 Apr 18 [cited 2018 Jan 12];2(2):34-8.
- Madersbacher H, Pilloni S. EFFICACY OF EXTRACORPOREAL MAGNETIC THERAPY (EXMI) IN COMPARISON TO STANDARD STRESS, URGE AND MIXED INCONTINENCE: A PROSPECTIVE TRIAL. [cited 2017 May 15];
- Antimicrobial susceptibility of some urinary tract clinical isolates to commonly used antibiotics | Inabo | *African Journal of Biotechnology* [Internet]. [cited 2017 May 15].
- NAYLOR GRE. A 16-month analysis of urinary tract infection in children. *J Med Microbiol* [Internet]. 1984 Feb 1 [cited 2018 Jan 12];17(1):31-6.
- Warren JW. Catheter-associated urinary tract infections. *Infect Dis Clin North Am* [Internet]. 1987 Dec [cited 2018 Jan 12];1(4):823-54.
- Ogbukagu CM, Anakwenze VN, Ekwealor CC, Ezemba CC, Ekwealor IA. Incidence of Urinary Tract Infections (UTI) amongst Patients Attending Primary Health Centres in Anambra State. *Adv Microbiol* [Internet]. 2016 Jun 15 [cited 2018 Jan 12];6(7):537-47.
- Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for Antimicrobial Treatment of Uncomplicated Acute Bacterial Cystitis and Acute Pyelonephritis in Women. *Clin Infect Dis* [Internet]. 1999 Oct [cited 2017 May 15];29(4):745-58.
- Increasing incidence of bacterial resistance to antibiotics by isolates from the urinary tract | Ozumba | *Nigerian Journal of Clinical Practice* [Internet]. [cited 2017 May 15].
- Obiogbolu CH, Okonko IO, Anyamere CO, Adedeji AO, Akanbi AO, Ogun AA, et al. Scientific research and essays. [Internet]. Vol. 4, Scientific Research and Essays. Academic Journals; 2009 [cited 2018 Jan 12]. 820-824 p.
- Oxford Textbook of Medicine Sections 1-12 and Index (Volume 1) by Weatherall, D J, Ledingham, J G G, and Warrell, D A (Eds.): Oxford University Press - Anybook Ltd. [Internet]. [cited 2018 Jan 12].
- Wagenlehner F, Umeh O, Huntington J. Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI)/pyelonephritis in hospitalised. *Infect Dis ...* [Internet]. 2014 [cited 2017 May 15];

13. Widerström M, Wiström J, Ferry S, Karlsson C, Monsen T. Molecular epidemiology of *Staphylococcus saprophyticus* isolated from women with uncomplicated community-acquired urinary tract infection. *J Clin Microbiol* [Internet]. 2007 May [cited 2017 May 15];45(5):1561-4.
14. Bhat R, Katy T, Place F. Pediatric urinary tract infections. *Emerg Med Clin North Am* [Internet]. 2011 [cited 2017 May 16];
15. Foxman B, Barlow R, D'Arcy H, Gillespie B. Urinary tract infection: self-reported incidence and associated costs. *Epidemiol* [Internet]. 2000 [cited 2017 May 16];
16. Hasan A, Nair D, Kaur J, Baweja G. Resistance patterns of urinary isolates in a tertiary Indian hospital. *J Ayub Med Coll* [Internet]. 2007 [cited 2017 May 16];
17. Manikandan S, Ganesapandian S, Singh M. Antimicrobial susceptibility pattern of urinary tract infection causing human pathogenic bacteria. *Asian J Med* [Internet]. 2011 [cited 2017 May 16];
18. Boye A, Siakwa P, Boampong J, Koffuor G. Asymptomatic urinary tract infections in pregnant women attending antenatal clinic in Cape Coast, Ghana. *E3 J Med* [Internet]. 2012 [cited 2017 May 16];
19. Johnson J, Delavari P, Azar M. Activities of a nitrofurazone-containing urinary catheter and a silver hydrogel catheter against multidrug-resistant bacteria characteristic of catheter-associated urinary. *Antimicrob agents* [Internet]. 1999 [cited 2017 May 16]
20. Oladeinde B, Omoregie R, Olley M. Urinary tract infection in a rural community of Nigeria. *North Am J* [Internet]. 2011 [cited 2017 May 16];
21. Aseffa A, Yohannes G. Antibiotic sensitivity pattern of prevalent bacterial pathogens in Gondar, Ethiopia. *East Afr Med J* [Internet]. 1996 Jan [cited 2018 Jan 12];73(1):67-71.
22. Akinloye O, Ogbolu DO, Akinloye OM, Terry Alli OA. Asymptomatic bacteriuria of pregnancy in Ibadan, Nigeria: a re-assessment. *Br J Biomed Sci* [Internet]. 2006 Jan 23 [cited 2018 Jan 12];63(3):109-12.
23. A. AO, O. IO, N. OI, E. OE, E. IO, I. OA. African journal of microbiology research. [Internet]. Vol. 1, African Journal of Microbiology Research. Academic Journals; 2007 [cited 2018 Jan 12]. 13-19 p.
24. EBSCOhost | 67351045 | Spectrum and Antimicrobial Susceptibility Pattern of Pathogens Causing Urinary Tract Infection-Experience in a Tertiary Care Setting. [Internet]. [cited 2018 Jan 12].
25. Sabir S, Ahmad Anjum A, Ijaz T, Asad Ali M, Ur Rehman Khan M, Nawaz M. Isolation and antibiotic susceptibility of *E. coli* from urinary tract infections in a tertiary care hospital. *Pakistan J Med Sci* [Internet]. 2014 Mar [cited 2018 Jan 12];30(2):389-92.
26. Ali K. Multiple Drug Resistance Pattern in Urinary Tract Infection Patients in Peshawar, Khyber Pukhtunkhwa (KPK) Province, Pakistan [Internet]. [cited 2018 Jan 12].
27. Ronald A. The etiology of urinary tract infection: Traditional and emerging pathogens. *Disease-aMonth* [Internet]. 2003 Feb [cited 2018 Jan 12];49(2):71-82.
28. Tessema B, Kassu A, Mulu A, Yismaw G. Pridominant isolates of urinary tract pathogens and their antimicrobial susceptibility patterns in Gondar University Teaching Hospital, north west Ethiopia. *Ethiop Med J* [Internet]. 2007 Jan [cited 2018 Jan 12];45(1):61-7.
29. Eshwarappa M, Dosegowda R, Aprameya IV, Khan MW, Kumar PS, Kempegowda P. Clinicomicrobiological profile of urinary tract infection in south India. *Indian J Nephrol* [Internet]. 2011 Jan [cited 2018 Jan 12];21(1):30-6.
30. Bean DC, Krahe D, Wareham DW. Antimicrobial resistance in community and nosocomial *Escherichia coli* urinary tract isolates, London 2005 - 2006. *Ann Clin Microbiol Antimicrob* [Internet]. 2008 Jun 18 [cited 2018 Jan 12];7(1):13.

31. Onanuga A, Awhowho GO. Antimicrobial resistance of *Staphylococcus aureus* strains from patients with urinary tract infections in Yenagoa, Nigeria. *J Pharm Bioallied Sci* [Internet]. 2012 Jul [cited 2018 Jan 12];4(3):226–30.
32. Okonko IO, Donbraye-Emmanuel OB, Ijandipe LA, Ogun AA, Adedeji AO, Udeze AO. Antibiotics Sensitivity and Resistance Patterns of Uropathogens to Nitrofurantoin and Nalidixic Acid in Pregnant Women with Urinary Tract Infections in Ibadan, Nigeria. *Middle-East J Sci Res* [Internet]. 2009 [cited 2018 Jan 13];4(2):105–9.
33. Okonko IO, Donbraye-Emmanuel OB, Ijandipe LA, Ogun AA, Adedeji AO, Udeze AO. Antibiotics Sensitivity and Resistance Patterns of Uropathogens to Nitrofurantoin and Nalidixic Acid in Pregnant Women with Urinary Tract Infections in Ibadan, Nigeria. *Middle-East J Sci Res* [Internet]. 2009 [cited 2018 Jan 12];4(2):105–9.
34. A AO, O IO, N OI, E OE, E IO, I OA. Incidence of urinary tract infections (UTI) among children and adolescents in Ile-Ife, Nigeria. *African J Microbiol Res* [Internet]. 2007 [cited 2018 Jan 13];13–9.
35. Brumfitt W, Hamilton-Miller JM. Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience. *J Antimicrob Chemother* [Internet]. 1998 Sep [cited 2018 Jan 13];42(3):363–71.

